Recent evidence has reported that DPP-4 inhibitors, including SITG and saxagliptin, reverse AD-like neurodegeneration by enhancing cognitive ability, reducing tau protein and neurofibrillary tangle aggregation, and protecting against Aβ accumulation in an AD mouse model [18]. This evidence concerns the gene MAPT and Alzheimer disease.